Indian Stock Market Updates: Brokerage Calls and Q2 Results
The Indian stock market has been abuzz with activity, as top brokerages have been releasing their commentary on various companies that have announced their Q2 results. In this article, we will delve into the updates from top brokerages on Swiggy, Bajaj Auto, Apollo Hospitals, Britannia Industries, Nykaa, and Trent.
Goldman Sachs Raises India to Overweight
Goldman Sachs has raised India to an Overweight position, expecting a 14% upside with an end-2026 NIFTY target of 29,000. This upgrade is driven by growth-supportive policies, earnings revival, under-positioning, and reasonable valuations. The brokerage firm favors sectors such as financials, consumer staples, durables, autos, defense, materials, and oil marketing companies.
Nuvama Initiates Coverage on Swiggy
Nuvama has initiated coverage on Swiggy with a Buy rating and a target price of Rs 510. According to Nuvama, Swiggy has evolved from an early entrant to become the second-largest food delivery company. The quick commerce market remains underpenetrated and is yet to mature, with Swiggy holding a 43% market share in food delivery, which is expected to grow in double digits with sharp profitability improvement.
Morgan Stanley on Bajaj Auto
Morgan Stanley has maintained an Outperform rating on Bajaj Auto with a target price of Rs 10,604. The brokerage firm believes that strong operational performance continues, with domestic two-wheeler growth revival identified as key. Growth will be driven by KTM restructuring, e
Additional Insights
A Resounding Vote of Confidence: Goldman Sachs Turns Bullish on India
In a significant development that has sent ripples across Dalal Street, global investment banking giant Goldman Sachs has upgraded its stance on India to ‘Overweight’. This move signals a renewed and powerful conviction in the Indian growth story, especially noteworthy as India had been a relative laggard in what has been a record-breaking year for emerging markets. For Indian investors, this is more than just a headline; it’s a strategic endorsement from one of the world’s most influential financial institutions.
Goldman Sachs isn’t just optimistic; they’ve put a number on it. The firm is projecting a robust 14% upside for Indian equities, setting an ambitious end-2026 Nifty target of 29,000. This upgrade is not based on fleeting sentiment but is anchored in a confluence of four key factors:
- Growth-Supportive Policies: A stable political environment and a continued focus on pro-growth reforms are seen as major catalysts.
- Earnings Revival: Corporate India is on the cusp of a strong earnings recovery cycle, which is expected to drive market performance.
- Under-Positioning: Global fund managers have been relatively underweight on India, leaving significant room for capital inflows as they rebalance their portfolios.
- Reasonable Valuations: Despite the recent run-up, valuations are considered reasonable when viewed in the context of the expected earnings growth.
Goldman’s Playbook: Sectors and Themes to Watch
Goldman Sachs has also laid out a clear roadmap for investors looking to capitalize on this optimistic outlook. Their favoured sectors represent a broad-based bet on the Indian economy:
- Financials: The backbone of the economy, expected to benefit from credit growth.
- Consumer (Staples & Durables): Betting on a revival in mass consumption.
- Autos: A direct play on rising disposable incomes and economic activity.
- Defence & Materials: Aligned with the government’s self-sufficiency (Atmanirbhar Bharat) push.
- Oil Marketing Companies (OMCs): Potential beneficiaries of stable energy policies and demand.
The key investment themes underpinning these sectoral picks are mass-consumption revival, self-sufficiency, the new economy, and high-growth segments. However, the report also flags potential risks, including earnings shortfalls if the expected recovery doesn’t materialize, unforeseen external headwinds, and concerns about AI-driven disruption across industries. As we delve into specific company reports, this macro backdrop provides the essential context for understanding the opportunities and challenges ahead.
The New-Age Tech Battleground: Swiggy’s IPO Buzz vs. Nykaa’s Analyst Divide
India’s new-age technology sector remains a hotbed of investor interest and intense debate. Two names currently dominating the conversation are the soon-to-be-listed Swiggy and the already-listed Nykaa, both facing unique opportunities and scrutiny.
Swiggy: Gearing Up for a Landmark Listing
With its IPO on the horizon, Swiggy is under the microscope. Brokerage firm Nuvama has initiated coverage with a bullish stance, setting the stage for what could be a highly anticipated public offering.
- Rating: Buy
- Target Price: ₹510
Nuvama’s thesis is built on Swiggy’s evolution into a dominant force in both food delivery and the burgeoning quick commerce space. They highlight that Swiggy commands a solid 43% market share in food delivery, a market poised for double-digit growth coupled with a sharp improvement in profitability. The real game-changer, however, could be Instamart. Positioned as a top-three player in quick commerce, Instamart is projected to deliver a staggering 75% Gross Order Value (GOV) Compound Annual Growth Rate (CAGR) between FY25 and FY28. Critically, Nuvama forecasts the consolidated business to achieve adjusted EBITDA break-even by Q2, a significant turnaround from an estimated loss of ₹1,910 crore in FY25.
Adding fuel to the fire, Morgan Stanley notes the board’s approval for a massive ₹10,000 crore fundraise via a Qualified Institutional Placement (QIP) or other modes. This pre-IPO capital infusion would bolster Swiggy’s cash reserves to approximately ₹17,000 crore, strengthening its balance sheet significantly. While this move implies a potential 9% equity dilution, it also signals Swiggy’s intent to aggressively compete, particularly against its listed rival Zomato.
Nykaa (FSN E-Commerce): A House Divided
FSN E-Commerce, the parent company of Nykaa, presents a classic case of analyst divergence, reflecting the market’s struggle to value a high-growth but high-spend business model. The views on the stock span the entire spectrum from ‘Sell’ to ‘Buy’.
The Bulls (Morgan Stanley & Jefferies):
- Morgan Stanley (Overweight, TP: ₹271): Focuses on the narrowing EBITDA losses in the fashion segment and management’s confidence in sustaining growth momentum across both beauty and fashion verticals.
- Jefferies (Buy, TP raised to ₹285): Highlights the impressive margin expansion that allowed EBITDA to outgrow revenue. They see the high marketing spends in the beauty segment not as a negative, but as a strategic investment to scale growth. The potential of Nykaa Now and the upcoming Nykaa Perfumery launch are seen as positive triggers.
The Bears (Macquarie & Citi):
- Macquarie (Underperform, TP: ₹150): Points to sustained margin pressure as a key concern. They note that beauty ad income growth has slowed and higher delivery costs in the fashion segment are eating into profits.
- Citi (Sell, TP: ₹175): Takes the most cautious stance, implying a potential 28.9% downside. Citi is concerned about the elevated marketing spends in beauty and personal care. While acknowledging margin improvement from lower losses in fashion, they see downside risks to future EBITDA estimates and value the company at a demanding 50 times FY27 estimated EV/Ebitda.
For investors, the Nykaa conundrum boils down to a simple question: Do you believe the current high expenditure is a necessary investment for long-term dominance, or an unsustainable cash burn in a competitive market?
Auto Sector Spotlight: Bajaj Auto’s Domestic Dilemma
Bajaj Auto continues to be a bellwether for the two-wheeler industry, but analysts are currently focused on a crucial tug-of-war between its strong export performance and its eroding market share in the domestic motorcycle segment.
- CLSA (Outperform, TP: ₹10,604): Maintains a positive view, citing strong continued operational performance. They believe growth will be driven by the KTM restructuring, a recovery in export markets, and a strong pipeline of new launches.
- BofA (Neutral, TP cut to ₹9,300): Takes a more balanced view. While acknowledging strong margins and the healthy growth contribution from exports and three-wheelers, BofA explicitly flags domestic market share losses as a significant concern.
- Jefferies (Hold, TP raised to ₹9,200): Echoes the concern about market share. Despite being positive on the overall Indian two-wheeler demand (forecasting 10% industry volume CAGR over FY25–FY28), Jefferies remains cautious on Bajaj Auto due to its declining share in its home market.
The key takeaway for Bajaj Auto is that while its international business and diversified portfolio provide a cushion, arresting the slide in the domestic motorcycle market is critical for its next leg of growth and a potential re-rating.
Consumer Sector: Navigating Staples Stability and Discretionary Demand
The consumer space offers a fascinating contrast between the steady, volume-led growth of staples and the sentiment-driven fluctuations of discretionary spending.
Britannia Industries: A Staple of Strength
FMCG major Britannia delivered a strong performance, beating earnings expectations and earning positive commentary from brokerages.
- Jefferies (Hold, TP raised to ₹6,350): Noted the strong revenue and EBITDA performance. Key input costs have eased sequentially, which is a positive for margins, although they remain higher year-on-year. The company’s continued focus on rural markets is expected to drive volume-led growth.
- Citi (Buy, TP raised to ₹7,000): Is more bullish, implying a 13.7% upside. Citi highlighted that the GST transition impacted Q2 growth by 2-2.5%, and expects normalised growth to resume from the third quarter. Management’s medium-term strategy to drive volume-led revenue growth is a key positive.
Trent: Facing Headwinds in Discretionary Spend
Tata Group’s retail arm, Trent, is feeling the pinch of muted consumer sentiment, with its recent results showing a slowdown.
- Jefferies (Hold, TP cut to ₹5,000): Directly points to a ‘growth deceleration’. While store additions have picked up, the crucial like-for-like (LFL) growth in the fashion segment remained in the low single digits.
- Macquarie (Outperform, TP: ₹7,000): Believes the weakness is temporary, caused by muted consumer sentiment and unseasonal rains. They remain optimistic, citing sustainable employee cost savings and the potential demand boost from a GST rate cut on small-ticket items.
- Morgan Stanley (Overweight, TP: ₹5,456): Acknowledged the slower growth trends in Q2, attributing them to similar factors as Macquarie. They noted that gross margins at both Westside and Zudio remained stable, which is a sign of operational resilience.
Healthcare & Pharma: High-Growth Stories in Focus
The defensive yet high-growth healthcare and pharmaceutical sectors are throwing up some compelling stories, with companies leveraging technology and specialized manufacturing capabilities.
Apollo Hospitals: Building an Integrated Healthcare Ecosystem
Morgan Stanley is particularly bullish on Apollo Hospitals, maintaining an Overweight rating and raising its target price from ₹8,058 to ₹8,813. The core of their thesis is the company’s transformation into an integrated, patient-centric healthcare platform powered by technology. They believe the convergence of Apollo’s digital arm, its vast distribution network, and its ongoing hospital expansion will create a differentiated and highly scalable franchise that the market is yet to fully appreciate. With delivery on track and supportive valuations, Morgan Stanley sees a clear path for value creation.
Divi’s Laboratories: The Custom Synthesis Powerhouse
Divi’s Lab emerged as a star performer, with its impressive results and strong growth commentary earning it upgrades and accolades from multiple brokerages.
- Morgan Stanley (Overweight, TP raised to ₹7,541): Praised the impressive Q2 performance, driven by a rising share of the high-margin custom synthesis business. They see ongoing capital expenditure and long-term contracts unlocking strong growth over FY27-FY28.
- Citi (Buy, TP raised to ₹9,140): Called the results ‘ahead of expectations’ with strong commentary on the high-potential peptide segment. Citi identifies Divi’s as its top India Pharma pick, citing its ambition to become a global leader in complex peptides and solid traction in custom synthesis.
- HSBC (Buy, TP: ₹7,400): Also highlighted the healthy beat driven by custom synthesis, despite pricing pressure in the generics segment. They are positive on the outlook as client interest in peptides continues to rise.
The consensus is clear: Divi’s Lab’s strategic focus on specialized, high-value areas like peptides and custom synthesis is paying off, positioning it for superior growth compared to peers facing headwinds in the traditional generics business.
Brokerage Radar: A Quick Roundup of Other Key Stocks
Amara Raja Energy & Mobility
Morgan Stanley (Underweight, TP cut to ₹875): Remains cautious due to slower-than-expected progress in the new energy business and a lack of new customer wins, despite a stable lead-acid battery business.
Petronet LNG
Macquarie (Underperform, TP: ₹260): Cites soft volumes and no near-term uptick expected in Kochi terminal utilisation. The company’s entry into petrochemicals is viewed as a move that could dilute returns.
Shriram Finance
Morgan Stanley (Overweight, TP: ₹540): Sees a 42% upside. Despite a profit miss due to one-off items, the core net interest income was strong. Stable credit costs and management’s guidance for 10-11% loan growth in FY26 are key positives.
Ashok Leyland
CLSA (Outperform, TP raised to ₹1,484): Notes strong operational performance and mid-teens EBITDA growth, supported by an industry revival and portfolio diversification.
Havells India
Kotak (Add, TP cut to ₹8,200): Flagged a subdued Q2 with weak profitability in the electronics segment being the key negative. Management remains confident of a turnaround by Q4.
Polycab India
Kotak (Add, FV raised to ₹4,600): Q2 results were driven by lumpy data centre sales. Gross margins improved despite competitive intensity, but export demand is showing sluggishness.
Jubilant FoodWorks
Citi (Buy, TP raised to ₹750): Implies a 46.3% upside. Revenue growth was supported by same-store sales growth. The company is on track to become debt-free by FY27, and successful execution could drive a re-rating.
Investor Takeaway: Navigating a Market of Divergence
The current market landscape presents a tale of two realities. On one hand, Goldman Sachs’ macro ‘Overweight’ call provides a powerful tailwind, suggesting that the broader market is poised for significant gains. This bullish sentiment is built on the strong fundamentals of the Indian economy and the prospect of an earnings revival.
On the other hand, a closer look at individual stocks reveals significant divergence. The Q2 earnings season has clearly separated the leaders from the laggards. Companies like Divi’s Lab are firing on all cylinders by focusing on specialized, high-growth niches. In contrast, players like Bajaj Auto and Trent are grappling with sector-specific headwinds, be it market share loss or muted consumer sentiment. The new-age tech space, exemplified by Swiggy and Nykaa, remains a high-risk, high-reward arena where the path to profitability is the ultimate prize.
For the Indian investor, the message is clear: while the tide may be rising, not all boats will be lifted equally. A stock-specific approach, grounded in thorough research of company fundamentals and a clear understanding of the diverse analyst opinions, is more crucial than ever. The coming quarters will be pivotal in determining whether the broad-based optimism translates into universal corporate performance.